Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 28, 2005. The report is a notification of changes in directors' interests in the company's Ordinary Shares, specifically relating to the GlaxoSmithKline US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on shareholding changes within a retirement fund.
Material Changes
The primary material change reported is a decrease in the number of Ordinary Share ADRs held by the GlaxoSmithKline US Retirement Savings Plan due to a fund movement on June 23, 2005:
- Previous Holdings: 18,344,554 ADRs
- New Holdings: 18,314,545 ADRs
- Average Price: $49.03
Two directors, Dr. J.P. Garnier and Dr. T. Yamada, are noted as potentially interested in these shares as beneficiaries of the discretionary fund.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items beyond the routine reporting of the retirement fund adjustment.
Key Facts for Investor Verification
- Verify the impact of the 30,009 ADR reduction on the total share count held by the US Retirement Savings Plan.
- Confirm the specific beneficial ownership status of Directors Dr. J.P. Garnier and Dr. T. Yamada regarding the fund's holdings.
- Note that this filing contains no operational or financial performance data for the period.